

- **Name:** Young Soo Park, MD, PhD.
 - **Current Position & Affiliation:** Professor at Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine
 - **Country:** Republic of Korea
-
- **Educational Background:**
 - 1992 – 1994: Pre-Medical, College of Medicine, Seoul National University, Republic of Korea
 - 1994 – 1999: MD, College of Medicine, Seoul National University, Republic of Korea
 - 2000 – 2004: Residency, Diagnostic Pathology, Seoul National University Hospital, Seoul National University, Republic of Korea
 - 2000 – 2004: PhD, Coursework, Pathology/PhD. Thesis 2009, College of Medicine, Seoul National University, Republic of Korea
 - 2007 – 2008: Fellowship, Diagnostic Pathology, Asan Medical Center, Seoul, Republic of Korea
 - **Professional Experience:**
 - 2005/05/01 – 2007/04/30: **Pathologist** – Armed Forces Seoul Hospital, Seoul, Republic of Korea
 - 2009/01/01 – 2009/08/31: **Appointed Pathologist** – Asan Medical Center, Seoul, Republic of Korea
 - 2009/09/01 – 2014/09/30: **Assistant Professor at Department of Pathology** - University of Ulsan College of Medicine
 - 2014/10/01 – 2020/08/31: **Associate Professor at Department of Pathology** - University of Ulsan College of Medicine
 - 2015/09/01 – 2017/08/31: **Research Fellow (visiting scholar) at Case Comprehensive Cancer Center** – Case Western Reserve University
 - **Professional Organizations:**
 - 2000 – Present: Korean Society of Pathologists
 - 2007 – Present: Korean Gastrointestinal Pathology Society
 - 2007 – 2015: Korean Pulmonary Pathology Society
 - 2010 – Present: Korean Cancer Association
 - 2010 – Present: Korean Society of Medical Oncology
 - **Main Scientific Publications:**
 1. J. H. Noh, J. Y. Shin, J. H. Lee, Y. S. Park, I. S. Lee, G. H. Kim, H. K. Na, J. Y. Ahn, K. W. Jung, D. H. Kim, K. D. Choi, H. J. Song, G. H. Lee, and H. Y. Jung, Clinical Significance of Epstein-Barr Virus and Helicobacter pylori Infection in Gastric Carcinoma. *Gut Liver*, 2022.
 2. K. Bang, J. Cheon, Y. S. Park, H. D. Kim, M. H. Ryu, Y. Park, M. Moon, H. Lee, and Y. K. Kang, Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. *Gastric Cancer*, 2022.

3. J. Yoon, S. Y. Yoo, Y. S. Park, K. D. Choi, B. S. Kim, M. W. Yoo, I. S. Lee, J. H. Yook, G. H. Kim, H. K. Na, J. Y. Ahn, J. H. Lee, K. W. Jung, D. H. Kim, H. J. Song, G. H. Lee, and H. Y. Jung, Reevaluation of the expanded indications in undifferentiated early gastric cancer for endoscopic submucosal dissection. *World J Gastroenterol*, 2022. **28**(15): p. 1548-1562
4. J. H. Kim, M. H. Ryu, Y. S. Park, J. Ma, S. Y. Lee, D. Kim, and Y. K. Kang, Predictive biomarkers for the efficacy of nivolumab as ≥ 3 (rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. *BMC Cancer*, 2022. **22**(1): p. 378.
5. H. K. Na, K. D. Choi, Y. S. Park, H. J. Kim, J. Y. Ahn, J. H. Lee, K. W. Jung, D. H. Kim, H. J. Song, G. H. Lee, and H. Y. Jung, Endoscopic scoring system for gastric atrophy and intestinal metaplasia: correlation with OLGA and OLGIM staging: a single-center prospective pilot study in Korea. *Scand J Gastroenterol*, 2022: p. 1-8.
6. H. D. Kim, M. H. Ryu, Y. S. Park, S. Y. Lee, M. Moon, and Y. K. Kang, Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab. *Gastric Cancer*, 2021.
7. Y. K. Kang, J. H. Yook, Y. K. Park, J. S. Lee, Y. W. Kim, J. Y. Kim, M. H. Ryu, S. Y. Rha, I. J. Chung, I. H. Kim, S. C. Oh, Y. S. Park, T. Son, M. R. Jung, M. H. Heo, H. K. Kim, C. Park, C. H. Yoo, J. H. Choi, D. Y. Zang, Y. J. Jang, J. Y. Sul, J. G. Kim, B. S. Kim, S. H. Beom, S. H. Cho, S. W. Ryu, M. C. Kook, B. Y. Ryoo, H. K. Kim, M. W. Yoo, N. S. Lee, S. H. Lee, G. Kim, Y. Lee, J. H. Lee, and S. H. Noh, PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. *J Clin Oncol*, 2021: p. JCO2002914
8. S. W. Kim, G. Jeong, M. H. Ryu, and Y. S. Park, Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens. *Pathology*, 2021.
9. S. J. Kim, H. G. Kang, K. Kim, H. Kim, F. Zetterberg, Y. S. Park, H. S. Cho, S. M. Hewitt, J. Y. Chung, U. J. Nilsson, H. Leffler, and K. H. Chun, Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression. *Gastric Cancer*, 2021.
10. S. W. Kim, J. Roh, H. S. Lee, M. H. Ryu, Y. S. Park, and C. S. Park, Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. *Gastric Cancer*, 2020.
11. G. S. Jeong, I. S. Lee, Y. S. Park, B. S. Kim, M. W. Yoo, J. H. Yook, and B. S. Kim, Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers. *J Gastric Cancer*, 2020. **20**(3): p. 233-244.
12. J. Y. Choi, S. E. Bae, J. Y. Ahn, J. H. Lee, Y. S. Park, D. H. Kim, K. D. Choi, H. S. Chang, H. J. Song, G. H. Lee, J. Choe, S. J. Jang, and H. Y. Jung, Novel Endoscopic Criteria for Predicting Tumor Invasion Depth in Superficial Esophageal Squamous Carcinoma. *J Korean Med Sci*, 2020. **35**(41): p. e336.
13. Y. S. Na, M. H. Ryu, Y. S. Park, C. W. Lee, J. K. Lee, Y. Park, J. M. Park, J. Ma, and Y. K. Kang, Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success. *Sci Rep*, 2020. **10**(1): p. 7996.
14. G. H. Kim, K. D. Choi, C. S. Gong, I. S. Lee, Y. S. Park, M. Han, H. K. Na, J. Y. Ahn, J. H. Lee, K. W. Jung, D. H. Kim, H. J. Song, G. H. Lee, and H. Y. Jung, Comparison of the treatment outcomes of endoscopic and surgical resection of GI stromal tumors in the stomach: a propensity score-matched case-control study. *Gastrointest Endosc*, 2020. **91**(3): p. 527-536.

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

15. H. Cho, M. H. Ryu, Y. Lee, Y. S. Park, K. H. Kim, J. H. Kim, Y. Park, S. M. Lee, C. W. Kim, B. S. Kim, M. W. Yoo, and Y. K. Kang, Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. *Oncologist*, 2019.
16. D. G. Mun, J. Bhin, S. Kim, H. Kim, J. H. Jung, Y. Jung, Y. E. Jang, J. M. Park, H. Kim, Y. Jung, H. Lee, J. Bae, S. Back, S. J. Kim, J. Kim, H. Park, H. Li, K. B. Hwang, Y. S. Park, J. H. Yook, B. S. Kim, S. Y. Kwon, S. W. Ryu, D. Y. Park, T. Y. Jeon, D. H. Kim, J. H. Lee, S. U. Han, K. S. Song, D. Park, J. W. Park, H. Rodriguez, J. Kim, H. Lee, K. P. Kim, E. G. Yang, H. K. Kim, E. Paek, S. Lee, S. W. Lee, and D. Hwang, Proteogenomic Characterization of Human Early-Onset Gastric Cancer. *Cancer Cell*, 2019. **35**(1): p. 111-124 e10.
17. H. Yang, D. Hong, S. Y. Cho, Y. S. Park, W. R. Ko, J. H. Kim, H. Hur, J. Lee, S. J. Kim, S. Y. Kwon, J. H. Lee, D. Y. Park, K. S. Song, H. Chang, M. H. Ryu, K. S. Cho, J. W. Kang, M. C. Kook, N. Thiessen, A. He, A. Mungall, S. U. Han, and H. K. Kim, RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. *Nat Commun*, 2018. **9**(1): p. 4439.
18. S. Seo, M. H. Ryu, Y. S. Park, J. Y. Ahn, Y. Park, S. R. Park, B. Y. Ryoo, G. H. Lee, H. Y. Jung, and Y. K. Kang, Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). *Gastric Cancer*, 2018.
19. M. H. Kang, H. Choi, M. Oshima, J. H. Cheong, S. Kim, J. H. Lee, Y. S. Park, H. S. Choi, M. N. Kweon, C. G. Pack, J. S. Lee, G. B. Mills, S. J. Myung, and Y. Y. Park, Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. *Nat Commun*, 2018. **9**(1): p. 1920.
20. I. S. Lee, H. J. Kang, Y. S. Park, M. H. Ryu, J. H. Yook, Y. K. Kang, and B. S. Kim, Prognostic impact of extranodal extension in stage 1B gastric carcinomas. *Surg Oncol*, 2018. **27**(2): p. 299-305.
21. Y. S. Park, J. H. Lee, D. B. Jung, H. B. Kim, J. H. Jung, S. Pak, Y. M. Ryu, H. J. Park, Y. Y. Park, H. Y. Jung, and S. J. Myung, MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma. *Sci Rep*, 2018. **8**(1): p. 17717
22. C. J. Cho, H. J. Kang, Y. M. Ryu, Y. S. Park, H. J. Jeong, Y. M. Park, H. Lim, J. H. Lee, H. J. Song, H. Y. Jung, S. Y. Kim, and S. J. Myung, Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. *Gastric Cancer*, 2018.